NEWS PM
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Dogwood Therapeutics (NASDAQ: DWTX) announced positive top-line data from their BHC IMC-2 Long-COVID study. The low-dose combination of valacyclovir 750 mg + celecoxib 200 mg twice daily showed clinically meaningful reductions in Long-COVID related fatigue and sleep disturbance compared to placebo. The higher dose (valacyclovir 1500 mg) was less effective due to GI adverse events.
Dogwood Therapeutics (NASDAQ: DWTX) announced positive top-line data from their BHC IMC-2 Long-COVID study. The low-dose combination of valacyclovir 750 mg + celecoxib 200 mg twice daily showed clinically meaningful reductions in Long-COVID related fatigue and sleep disturbance compared to placebo. The higher dose (valacyclovir 1500 mg) was less effective due to GI adverse events.
The study's results will inform the design of a planned Phase 2 study with approximately 200 participants.
The company also has two other assets: Halneuron® in Phase 2b for chemotherapy-induced neuropathic pain and IMC-1 which is Phase 3-ready for fibromyalgia.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2493Followers
107Following
27KVisitors
Follow